NASDAQ:RDUS

Radius Health - RDUS Stock Forecast, Price & News

$10.08

0.00 (0.00%)

(As of 09/16/2022)

Add

Compare

Today's Range: $10.08
▼
$10.08
50-Day Range: $10.07
▼
$10.22
52-Week Range: $4.97
▼
$23.00

Volume: 4,802 shs
Average Volume: 1.17 million shs
Market Capitalization: $480.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.60

Radius Health MarketRank™ Forecast

Analyst Rating: Hold
1.80 Rating Score
Upside/Downside: 14.7% Downside
$8.60 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -1.53
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$40,401 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.18) to $0.38 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

1050th out of 1,072 stocks

Pharmaceutical Preparations Industry

520th out of 534 stocks

0.9

Analyst's Opinion

Consensus Rating
Radius Health has received a consensus rating of Hold. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $8.60, Radius Health has a forecasted downside of 14.7% from its current price of $10.08.
Amount of Analyst Coverage
Radius Health has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for RDUS.

0.0

Dividend Strength

Dividend Yield
Radius Health does not currently pay a dividend.
Dividend Growth
Radius Health does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Radius Health has received a 59.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Parathyroid hormones" products. See details.
Environmental Sustainability
The Environmental Impact score for Radius Health is -1.53.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Radius Health this week, compared to 2 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Radius Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,401.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.73% of the stock of Radius Health is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Radius Health are expected to grow in the coming year, from ($0.18) to $0.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Radius Health is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Radius Health is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Radius Health (NASDAQ:RDUS) Stock

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Stock News Headlines

October 6, 2022 | americanbankingnews.com

Radius Health (NASDAQ:RDUS) Coverage Initiated by Analysts at StockNews.com

September 28, 2022 | americanbankingnews.com

Radius Health (NASDAQ:RDUS) Research Coverage Started at StockNews.com

August 15, 2022 | finance.yahoo.com

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

August 11, 2022 | markets.businessinsider.com

FDA Accepts Menarini Group and Radius Health's Filing Under Priority Review For Breast Cancer Candidate

August 11, 2022 | finance.yahoo.com

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

July 28, 2022 | finance.yahoo.com

Mass. M&A activity picks up among life sciences firms

July 15, 2022 | seekingalpha.com

Golden Age Of Merger Arb: Radius

July 11, 2022 | finance.yahoo.com

Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health

July 8, 2022 | finance.yahoo.com

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

July 7, 2022 | finance.yahoo.com

Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

July 7, 2022 | benzinga.com

Radius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

July 7, 2022 | barrons.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, RADA, GRRB, EPZM

July 7, 2022 | finance.yahoo.com

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

July 6, 2022 | benzinga.com

Moore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm

July 6, 2022 | apnews.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VMW, CMAX, RDUS, FSTX

July 6, 2022 | apnews.com

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm

June 28, 2022 | markets.businessinsider.com

Short Volatility Alert: Radius Health, Inc.

June 28, 2022 | benzinga.com

Equity Alert - The M&A Class Action Firm Announces an Investigation of Radius Health, Inc. - RDUS

June 27, 2022 | apnews.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAK

June 25, 2022 | benzinga.com

RADIUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of RDUS and Encourages Investors to Contact the Firm

June 24, 2022 | seekingalpha.com

Hot Stocks: KMX, BB rise on earnings; WOLF upgrade; RDUS slips after previous day's gains

June 24, 2022 | bizjournals.com

Equity firms to take Radius Health private for $890M

June 24, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Radius Health

June 23, 2022 | apnews.com

RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to Shareholders

June 23, 2022 | marketwatch.com

Radius Health Shares Leap on Deal to Be Taken Private >RDUS

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Company Calendar

Last Earnings: 8/09/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RDUS
CUSIP: N/A
CIK: 1428522
Web: www.radiuspharm.com
Phone: (617) 551-4000
Fax: 617-551-4701
Employees: 293
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.60
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: -14.7%
Consensus Rating: Hold
Rating Score (0-4): 1.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,180,000.00
Net Margins: -30.73%
Pretax Margin: -30.73%
Return on Equity: N/A
Return on Assets: -40.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.67
Quick Ratio: 1.52

Sales & Book Value

Annual Sales: $229.97 million
Price / Sales: 2.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($5.74) per share
Price / Book: -1.76

Miscellaneous

Outstanding Shares: 47,620,000
Free Float: 46,796,000
Market Cap: $480.01 million
Optionable: Optionable
Beta: 0.51

Key Executives

Mr. G. Kelly Martin (Age 63)
CEO, Pres & Director
Comp: $600.48k

Ms. Danielle Holtschlag (Age 44)
VP of Sales & Head of U.S. Sales Channels
Comp: $299.3k

Ms. Chhaya Shah (Age 58)
Sr. VP & Chief Bus. Officer
Comp: $631.62k

Dr. Stavros C. Manolagas
Founder & Member of the Scientific Advisory Board

Dr. John Thomas Potts Jr. (Age 90)
DSc, M.D., Founder & Member of the Scientific Advisory Board

Dr. Michael Rosenblatt M.D. (Age 74)
Founder, Board Observer & Member of Scientific Advisory Board

Dr. John A. Katzenellenbogen
Founder & Member of the Scientific Advisory Board

Mr. Mark William Conley CPA (Age 60)
VP, CFO, Principal Accounting Officer & Treasurer

Mr. Peter A. Schwartzman
Head of Corp. Fin.

Ethan Holdaway
Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RDUS Stock - Frequently Asked Questions

Should I buy or sell Radius Health stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RDUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View RDUS analyst ratings or view top-rated stocks.
What is Radius Health's stock price forecast for 2022?: 5 equities research analysts have issued twelve-month price targets for Radius Health's shares. Their RDUS share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.60 in the next year. This suggests that the stock has a possible downside of 14.7%.
View analysts price targets for RDUS or view top-rated stocks among Wall Street analysts.
How have RDUS shares performed in 2022?: Radius Health's stock was trading at $6.92 at the beginning of the year. Since then, RDUS shares have increased by 45.7% and is now trading at $10.08.
View the best growth stocks for 2022 here.
When is Radius Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RDUS earnings forecast.
How were Radius Health's earnings last quarter?: Radius Health, Inc. (NASDAQ:RDUS) posted its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.35. The biopharmaceutical company had revenue of $58.29 million for the quarter, compared to analyst estimates of $67.95 million.

What other stocks do shareholders of Radius Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).
What is Radius Health's stock symbol?: Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How do I buy shares of Radius Health?: Shares of RDUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Radius Health's stock price today?: One share of RDUS stock can currently be purchased for approximately $10.08.
How much money does Radius Health make?: Radius Health (NASDAQ:RDUS) has a market capitalization of $480.01 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.
How many employees does Radius Health have?: The company employs 293 workers across the globe.
How can I contact Radius Health?: Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.

This page (NASDAQ:RDUS) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Radius Health - RDUS Stock Forecast, Price & News

Radius Health MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Radius Health (NASDAQ:RDUS) Stock

RDUS Stock News Headlines

RDUS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RDUS Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™